Prospective Observation of Cardiac Safety With Proteasome Inhibition
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
- Status
- COMPLETED
- Phase
- PHASE2
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- N/A
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies
- Status
- COMPLETED
- Phase
- N/A
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
- Status
- UNKNOWN
- Phase
- PHASE2
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
- Status
- COMPLETED
- Phase
- NA
A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE3
Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Treatment Optimization in Patients With Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib
- Status
- WITHDRAWN
- Phase
- PHASE2
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
CART-19 for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers
- Status
- COMPLETED
- Phase
- NA
UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Status
- TERMINATED
- Phase
- PHASE2